Figure 5.
Figure 5. Cytolytic activity of the CTL lines generated by stimulation with CD40-B cells pulsed with newly identified epitopes. CD8+ T cells from CMV-seropositive donors were stimulated with peptide-pulsed autologous CD40-B cells. CMVpp65-derived synthetic peptides used were CEDVPSGKL (pp65232-240) to be presented by HLA-B*4001 (A), HERNGFTVL (pp65267-275) by HLA-B*4001 (B), AELEGVWQPA (pp65525-534) by HLA-B*4006 (C), QYDPVAALF (pp65341-349) by HLA-Cw*0401 (D), VVCAHELVC (pp65198-206) by HLA-Cw*0801 (E) or Cw*1502 (F). One week after the third stimulation, cytolysis of CTL lines was assessed by 51Cr release assay against LCL/pp65 (▪), LCL/EGFP (○), or 1 μM peptide-pulsed LCL/EGFP (•) over a range of E/T ratios as indicated. The origin of target cells was autologous (panel F) or allogeneic [panels A-B, N06 (B*4001+); panel D, P01(Cw*0401+); panels C and E, N03(B*4006, Cw*0801+)].

Cytolytic activity of the CTL lines generated by stimulation with CD40-B cells pulsed with newly identified epitopes. CD8+ T cells from CMV-seropositive donors were stimulated with peptide-pulsed autologous CD40-B cells. CMVpp65-derived synthetic peptides used were CEDVPSGKL (pp65232-240) to be presented by HLA-B*4001 (A), HERNGFTVL (pp65267-275) by HLA-B*4001 (B), AELEGVWQPA (pp65525-534) by HLA-B*4006 (C), QYDPVAALF (pp65341-349) by HLA-Cw*0401 (D), VVCAHELVC (pp65198-206) by HLA-Cw*0801 (E) or Cw*1502 (F). One week after the third stimulation, cytolysis of CTL lines was assessed by 51Cr release assay against LCL/pp65 (▪), LCL/EGFP (○), or 1 μM peptide-pulsed LCL/EGFP (•) over a range of E/T ratios as indicated. The origin of target cells was autologous (panel F) or allogeneic [panels A-B, N06 (B*4001+); panel D, P01(Cw*0401+); panels C and E, N03(B*4006, Cw*0801+)].

Close Modal

or Create an Account

Close Modal
Close Modal